Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1995-12-11
1998-05-12
Chan, Christina Y.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 29, 436501, G01N 33566, C12Q 102
Patent
active
057503532
ABSTRACT:
The invention features a method for determining whether a candidate compound is a non-peptide agonist of a peptide hormone receptor. In this method, a candidate compound is exposed to a form of the peptide hormone receptor which has an enhanced ability to amplify the intrinsic activity of a non-peptide agonist. The second messenger signaling activity of the enhanced receptor is measured in the presence of the candidate compound, and compared to the second messenger signaling activity of the enhanced receptor measured in the absence of the candidate compound. A change in second messenger signaling activity indicates that the candidate compound is an agonist. An increase in second messenger signaling activity indicates that the compound is either a full or partial positive agonist; a decrease in second messenger signaling activity indicates that the compound is an inverse (also termed a `negative`) agonist.
REFERENCES:
patent: 5521175 (1996-05-01), Castro Pineiro et al.
Allen et al., Proc. Natl. Acad. Sci. USA, "G-protein-coupled receptor genes as protooncogenes: Constitutively activating mutation of the .alpha..sub.1.beta. -adrenergic receptor enhances mitogenesis and tumorigenicity," 88:11354-58, 1991.
Barker et al., J. Biol. Chem., "Constitutively Active 5-Hydroxytryptamine.sub.2C Receptors Reveal Novel Inverse Agonist Activity of Receptor Ligands," 269:11687-90, 1994.
Beinborn et al., Nature, "A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non-peptide antagonists," 362:348-50, 1993.
Black et al., Nature, "Inverse agonists exposed," 374:214-15, 1995.
Bond et al., Nature, "Physiological effects of inverse agonists in transgenic mice with myocardial over-expression of the .beta..sub.2 -adrenoceptor," 374:272-76, 1995.
Chen et al., Am. Soc. Pharm., Exper. Therapeutics, "Physiological Disposition and Metabolism of L-365,260, a Potent Antagonist of Brain Cholecystokinin Receptor, in Laboratory Animals," 20:390-95, 1992.
Chu et al., Gastroenterology, "Effect of Endogenous Hypergastrinemia on Gastrin Receptor Expressing Human Colon Carcinoma Transplanted to Athymic Rats," 109:1415-20, 1995.
Clapham, Cell, "Mutations in G Protein-Linked Receptors: Novel Insights on Disease," 75:1237-39, 1993.
Coughlin, Current Opinion in Cell Biology, "Expending horizons for receptors coupled to G proteins: diversity and disease," 6:191-97, 1994.
De Lean et al., J. Biol. Chem., "A Ternary Complex Model Explains the Agonist-specific Binding Properties of the Adenylate Cyclase-coupled .beta.-Adrenergic Receptor," 255:7108-17, 1980.
Dethloff et al., Drug Metab., "Cholecystokinin Antagonists--a Toxicologic Perspective," 24:267-93, 1992.
Ding et al., Gastroenterology, "Cholecystokinin-B Receptor Ligands of the Dipeptoid Series Act as Agonists on Rat Stomach Histidine Decarboxylase," 109:1181-87, 1995.
Dourish et al., Science, "Postponement of Satiety by Blockade of Brain Cholecystokinin (CCK-B) Receptors," 245:1509-11, 1989.
Harro et al., Trends Pharmacol. Sci., "CCK in animal and human research on anxiety," 14:244-49, 1993.
Hausdorff et al., J. Biol. Chem., "A Mutation of the .beta..sub.2 -Adrenergic Receptor Impairs Agonist Activation of Adenylyl Cyclase without Affecting High Affinity Agonist Binding," 265:1388-93, 1990.
Hogger et al., J. Biol. Chem., "Activating and Inactivating Mutations in N- and C-terminal i3 Loop Junctions of Muscarinic Acetylcholine Hm1 Receptors," 270:7405-10, 1995.
Horwell, Eur. J. Med. Chem., "Peptoid Approaches in the Design of Antagonists of Substance P and Cholecystokinin," 30 Suppl.:537S-550S, 1995.
Horwell et al., J. Med. Chem., "Rationally Designed `Dipeptoid` Analogues of CCK .alpha.-methyltryptophan Derivatives as Highly Selective and Orally Active Gastrin and CCK-B Antagonists with Potent Anxiolytic Properties," 34:404-14, 1991.
Ishizuka et al., Ann. Surg., "The Effect of Gastrin on Growth of Human Stomach Cancer Cells," 215:528-535, 1992.
Kenakin, Trends Pharmacol. Sci., "On the definition of efficacy," 15:408-09, 1994.
Kjelsberg et al., J. Biol. Chem., "Constitutive Activation of the .alpha..sub.1B -Adrenergic Receptor by All Amino Acid Substitutions at a Single Site," 267:1430-33, 1992.
Kopin et al., J. Biol., "The Role of the Cholecystokinin-B/Gastrin Receptor Transmembrane Domains in Determining Affinity for Subtype-selective Ligands," 270:5019-23, 1995.
Kopin et al., Proc. Natol. Acad. Sci.USA, "Expression cloning and characterization of the canine parietal cell gastrin receptor," 89:3605-09, 1992.
Kopp et al., N.E. J. of Medicine, "Brief Report: Congenital Hyperthyroidism Caused by a Mutation in the Thyrotropin-Receptor Gene," 332:150-54, 1995.
Latronico et al., J. Clinical Endocrinology and Metabolism, "A Novel Mutation of the Luteinizing Hormone Receptor Gene Causing Male Gonadotropin-Independent Precocious Puberty," 80:2490-94, 1995.
Lazareno et al., Trends Pharmacol. Sci., "Estimation of antagonist K.sub.b from inhibition curves in functional experiments: alternatives to the Cheng-Prusoff equation," 14:237-39, 1993.
Lee et al., J. Biol. Chem., "The Human Brain Cholecystokinin-B/Gastrin Receptor," 268:8164-69, 1993.
Leff, Trends Pharmacol.Sci., "The two-state model of receptor activation," 16:89-97, 1995.
Lefkowitz et al., Trends Pharmacol. Sci., "Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins," 14:303-07, 1993.
Lefkowitz, Nature, "Turned on to ill effect," 365:603-04, 1993.
Lloyd et al., Physiology of the gastrointestinal tract, "Peripheral Regulation of Gastrin Acid Secretion," 1185-1226, 1994.
Lotti et al., Eur. J. of Pharmacology, "A new potent and seletive non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260," 162:273-80, 1989.
Matus-Leibovitch et al., J. Biol. Chem., "Truncation of the Thyrotropin-releasing Hormone Receptor Carboxyl Tail Causes Constitutive Activity and Leads to Impaired Responsiveness in Xenopus oocytes and AtT20 Cells," 270:1041-47, 1995.
McPherson, J. Pharmacol. Meth., "Analysis of Radioligand Binding Experiments. A Collection of Computer Programs for the IBM PC," 14:213-28, 1995.
Milligan et al., Trends Pharmacol. Sci., "Inverse agonism: pharmacological curiosity or potential therapeutic strategy?" 16:10-13, 1995.
Nishida et al., J. Pharm. and Experimental Therapeutics, "Pharmacological Profile of in-3-yl!-3-(3-methylphenyl)urea (YM022), a New Potent and Selective Gastrin/Cholecystokinin-B Receptor Antagonist, in Vitro and in Vivo," 269:725-31, 1994.
Nishida et al., J. Pharm. and Experimental Therapeutics, "YM022 epin-3-yl!-3-(3-methylphenyl)urea}, a Potent and Selective Gastrin/Cholecystokinin-B Receptor Antagonist, Prevents Gastric and Duodenal Lesions in Rats," 270:1256-61, 1994.
Parker et al., J. Biol. Chem., "Truncation of the Extended Carboxyl-terminal Domain Increases the Expression and Regulatory Activity of the Avian .beta.-adrenergic Receptor," 266:9987-96, 1991.
Parma et al., Mol. and Cel. Endocrinology, "Constitutively active receptors as a disease-causing mechanism," 100:159-62, 1994.
Parma et al., Nature, "Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas," 365:649-51, 1993.
Parma et al., Molecular Endocrinology, "Somatic Mutations Causing Constitutive Activity of the Thyrotropin Receptor Are the Major Cause of Hyperfunctioning Thyroid Adenomas: Identification of Additional Mutations Activating Both the Cyclic Adenosine 3', 5'-Monophosphate and Inositol Phosphate-Ca.sup.2+ Cascades," 9:725-33, 1995.
Paschke et al., J. Clinical Endocrinology and Metabolism, "Identification and Functional Characterization of Two New Somatic Mutations Causing Constitutive Activation of the Thyrotropin Receptor in Hyperfunctioning Autonomous Adenomas of the Thyroid," 79:1785-89, 1994.
Patchett et al., Proc. Natl. Acad. Sci. USA, "Design and biological activities of L-163,191 (MK-0677): A potent, orally active growth hormone secretagogue," 92:7001-05, 1995.
Patel et al., Molecular Pharmacology, "Biological Properties of the Benzodiazepine Amidine Derivative L-740,093, a Cholecysto
Beinborn Martin
Kopin Alan S.
Cech Emma
Chan Christina Y.
New England Medical Center Hospitals Inc.
LandOfFree
Assay for non-peptide agonists to peptide hormone receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assay for non-peptide agonists to peptide hormone receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assay for non-peptide agonists to peptide hormone receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-978322